Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

Stock Information for Trex Wind Down Inc Com (New)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Trex Wind Down Inc Com (New)

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance
TIMBER PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Timber Pharmaceuticals, Inc. - TMBR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ESTE, PR, TMBR
Lifshitz Law PLLC Announces Investigations of TMBR, PR, ESTE, and CELL
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Timber Pharmaceuticals, Inc. Buyout
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CTG, TMBR, HEP, CEQP

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.